SCHEMBL30043335

SCHEMBL30043335

O=C1CC[C@@H](N2C(=O)c3ccc(C(=O)O)cc3C2=O)C(=O)N1

nearest known ligand 0.70

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 18/20 0.70
▸ DDB1 Q16531 13/20 0.69
▸ ALDH1A1 P00352 1/20 0.66
▸ CHRM2 P08172 1/20 0.66
▸ OPRM1 P35372 1/20 0.66
▸ IKZF3 Q9UKT9 1/20 0.66
▸ CYP1A2 P05177 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ IKZF1 Q13422 1/20 0.54
▸ IKZF2 Q9UKS7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10154012 1.00 CRBN (0.70) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL18475485 0.90 CRBN (0.59) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL4450512 0.89 CRBN (0.69) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL31403507 0.89 CRBN (0.69) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL28881272 0.88 CRBN (0.62) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL31063667 0.87 CRBN (0.64) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL31063657 0.87 CRBN (0.61) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL18306860 0.86 CRBN (0.66) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL30254191 0.86 CRBN (0.66) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL28950971 0.86 CRBN (0.66) CRBNDDB1ALDH1A1CHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4107158-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF Nurix Therapeutics, Inc. (US) 2022-12-28 — — EP disclosed
CN-115335381-A Bifunctional degradants of interleukin-1 receptor-associated kinase and therapeutic uses thereof 新锐思生物制药股份有限公司 2022-11-11 — — CN disclosed
Send feedback